More News! 25 Mar 2019
Swedish Biotech’s Stock Severely Hit by Failure of Biogen’s Alzheimer’s Drug
The failure of Biogen’s Alzheimer’s disease drug in a phase III trial last week caused BioArctic’s stock price to plummet by 35% on Nasdaq Stockholm. The Swedish company has just begun a phase III trial of its own Alzheimer’s treatment. Last week, Biogen and its pharma collaborator Eisai discontinued the phase III development of an […]